A new product on the market makes it possible to vaccinate pigs as young as day one against the serious influenza A virus in swine (IAV-S), said Boehringer Ingelheim (BI) in a news release on Monday.
“With demonstrated efficacy and safety, as well as the flexibility of timing and method of administration, Ingelvac Provenza fills an unmet need in the swine industry, and will establish a new way of thinking about influenza protection,” the company said.
“Vaccinating pigs as young as one day old provides protection before pigs are most vulnerable,” said Christa Goodell, DVM, technical manager for the Boehringer Ingelheim U.S. Swine Business, in the release. The vaccine is administered intranasally and “provides a direct means of protection at the site of natural IAV-S infection.”
Ingelvac Provenza is the first live attenuated influenza vaccine (LAIV) for growing pigs, according to BI, and the company says it offers a new level of protection against the threat of influenza virus strains H1N2 AND H3N21. Live attenuated influenza vaccine has been evaluated to reduce virus shedding in the presence of maternal antibodies.
Del Birkhofer, head of the U.S. swine business and Newport Laboratories, explained this ongoing threat: “IAV-S can have a widespread impact on the health of the pig population and subsequently, the productivity and profitability for producers. Studies have shown that uncomplicated IAV-S infection can lead to an estimated loss of more than $3 per pig, and when IAV-S is present with concurrent infections, the loss can be greater than $10 per pig.”